Innovation Ventures Search Results
Narrow Your Results
Filter
Technology PatentStatus
- All (2)
- Issued Patent (0)
- National Phase Entry (0)
- PCT Filing (0)
- Provisional Filing (0)
- US Non-Provisional Filing (2)
Technology Categories
- All (2)
- Diagnostics (0)
- Educational Tools and Consumer Products (0)
- Medical Devices (0)
- Other (0)
- Research Tools (0)
- Software (0)
- Therapeutics (2)
Technology Stage Of Development
- All Results (2)
- Cell and Gene Therapy (0)
- Organoids (0)
- Other Biologics and Macromolecules (0)
- Small Molecule (2)
- Vaccines (0)
Results (2)
Repurposing Barasertib for Idiopathic Pulmonary Fibrosis
Repurposing a phase I/II compound (AURKB inhibitor - barasertib) for idiopathic pulmonary fibrosis therapy.
Therapeutic Inhibition of the WT1-MYCN-PLK1 Axis for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Repurposing Volasertib, a potent PLK1 inhibitor, as a treatment of Idiopathic Pulmonary Fibrosis
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
